In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within in non-small cell lung cancer tumor cells; the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC). GlobalData uses proprietary data and analytics to provide a comprehensive report on the alk tests devices market, including market shares of different players within New Zealand. Buy the latest report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights New Zealand ALK Tests Market Share

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

In 2022, GlobalData’s Market Model methodology determined that the leading player in the alk tests market in New Zealand was Abbott Laboratories followed by Biocare Medical, Qiagen, Thermo Fisher Scientific, F. Hoffmann-La Roche, Agilent Technologies, ZytoVision, Sysmex, Bio-Rad Laboratories, New England Biolabs, Danaher, EntroGen, Amoy Diagnostics, Cancer Diagnostics and Panagene.

This segment includes Immunohistochemistry (IHC) Tests, In Situ Hybridization (ISH) Tests, and Nucleic Acid Amplification Tests (NAATs).

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the alk tests devices market within New Zealand was expected to be over $7.7727e+006m in 2022.

For the latest complete market share analysis of alk tests device market in New Zealand, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.